Cargando…

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

Mostrar otras versiones (1)

The emergence of SARS-CoV-2 variants has raised concerns about altered sensitivity to antibody-mediated immunity. The relative resistance of SARS-CoV-2 variants B.1.1.7 and B.1.351 to antibody neutralization has been recently investigated. We report that another emergent variant from Brazil, P.1, is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Pengfei, Casner, Ryan G., Nair, Manoj S., Wang, Maple, Yu, Jian, Cerutti, Gabriele, Liu, Lihong, Kwong, Peter D., Huang, Yaoxing, Shapiro, Lawrence, Ho, David D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053237/ https://www.ncbi.nlm.nih.gov/pubmed/33887205 http://dx.doi.org/10.1016/j.chom.2021.04.007

Ejemplares similares

Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization
por: Wang, Pengfei, et al.
Publicado: (2021)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
por: Cerutti, Gabriele, et al.
Publicado: (2021)

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization
por: Wang, Pengfei, et al.
Publicado: (2021)

Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies
por: Cerutti, Gabriele, et al.
Publicado: (2021)

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
por: Wang, Pengfei, et al.
Publicado: (2021)

Changes in serum-neutralizing antibody potency and breadth post-SARS-CoV-2 mRNA vaccine boost
por: Nair, Manoj S., et al.
Publicado: (2023)

Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class
por: Rapp, Micah, et al.
Publicado: (2021)

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
por: Cerutti, Gabriele, et al.
Publicado: (2021)

An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses
por: Liu, Lihong, et al.
Publicado: (2022)

Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants
por: Anichini, Gabriele, et al.
Publicado: (2021)

SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease
por: Wang, Pengfei, et al.
Publicado: (2020)

Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination
por: Iketani, Sho, et al.
Publicado: (2021)

Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking
por: Liu, Lihong, et al.
Publicado: (2023)

Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses
por: Banach, Bailey B., et al.
Publicado: (2021)

Human antibodies can neutralize SARS-CoV-2
por: Catalan-Dibene, Jovani
Publicado: (2020)

Thermodynamically coupled biosensors for detecting neutralizing antibodies against SARS-CoV-2 variants
por: Zhang, Jason Z., et al.
Publicado: (2022)

Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants
por: Xu, Jianliang, et al.
Publicado: (2021)

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
por: Edara, Venkata Viswanadh, et al.
Publicado: (2021)

A Multivariant Surrogate Neutralization Assay Identifies Variant-Specific Neutralizing Antibody Profiles in Primary SARS-CoV-2 Omicron Infection
por: Springer, David Niklas, et al.
Publicado: (2023)

INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants
por: Andrade, Viviane M., et al.
Publicado: (2021)

Kinetics of Neutralizing Antibody Responses Against SARS-CoV-2 Delta Variant in Patients Infected at the Beginning of the Pandemic
por: Choe, Pyoeng Gyun, et al.
Publicado: (2022)

Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies
por: Zhong, Chaojie, et al.
Publicado: (2021)

A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients
por: Karaba, Andrew H., et al.
Publicado: (2022)

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
por: Wang, Qian, et al.
Publicado: (2022)

IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2
por: Hale, Malika, et al.
Publicado: (2022)

Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75
por: Wang, Qian, et al.
Publicado: (2022)

SARS-CoV-2 variant evades antibodies whilst maintaining fitness
por: Flemming, Alexandra
Publicado: (2021)

Outliers Matter—Correlation between S1 IgG SARS-CoV-2 Antibodies and Neutralizing SARS-CoV-2 Antibodies
por: Hocher, Berthold, et al.
Publicado: (2022)

Convalescent plasma donors show enhanced cross‐reactive neutralizing antibody response to antigenic variants of SARS‐CoV‐2 following immunization
por: Harvala, Heli, et al.
Publicado: (2022)

Neutralizing antibodies in convalescent patients
por: Uhl, Lion F. K., et al.
Publicado: (2020)

CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant
por: Fumagalli, Marcilio Jorge, et al.
Publicado: (2022)

A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern
por: Brinkkemper, Mitch, et al.
Publicado: (2021)

Serum Neutralization Against SARS-CoV-2 Variants Is Heterogenic and Depends on Vaccination Regimen
por: Jäger, Michael, et al.
Publicado: (2022)

Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron
por: Wang, Lidong, et al.
Publicado: (2023)

Neutralizing antibody responses to SARS-CoV-2: A population based seroepidemiological analysis
por: Sharma, Pragya, et al.
Publicado: (2022)

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
por: Pérez-Then, Eddy, et al.
Publicado: (2022)

Massively multiplexed affinity characterization of therapeutic antibodies against SARS-CoV-2 variants
por: Engelhart, Emily, et al.
Publicado: (2022)

High titer of antibody against the SARS-CoV-2 spike protein among patients receiving neutralizing antibody cocktail therapy with REGN-COV
por: Sasaki, Hiroaki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_30occt18e4sgp1andtfekovh8s